Rasagiline (Azilect) for Parkinson's Disease
Also known as: Azilect
A selective MAO-B inhibitor studied as a potential disease-modifying agent in Parkinson's, with both symptomatic and possible neuroprotective effects.
Mechanism of Action
Rasagiline irreversibly inhibits monoamine oxidase type B (MAO-B), the primary enzyme degrading dopamine in the brain. This increases synaptic dopamine availability. Additionally, rasagiline's propargylamine moiety activates anti-apoptotic pathways (Bcl-2 upregulation, mitochondrial stabilization) independent of MAO-B inhibition, suggesting neuroprotective potential.
General mechanism: Irreversible selective MAO-B inhibitor. Increases synaptic dopamine. Propargylamine-mediated anti-apoptotic signaling.
Current Evidence
ADAGIO trial suggested possible disease-modifying effects with early initiation (1mg dose demonstrated changes in outcome measures vs. delayed start), though the 2mg arm was inconclusive. The delayed-start design was novel but interpretation remains debated. Used as monotherapy in early PD and as levodopa adjunct.
Clinical Status: FDA-approved for early and adjunctive Parkinson's treatment. Generic available. Disease modification claim not established.
Safety Profile
Well-tolerated. Headache, arthralgia, dyspepsia. Minimal tyramine interaction risk (unlike non-selective MAO inhibitors). Serotonin syndrome risk with SSRIs.
Key Research Questions
- Does rasagiline's propargylamine moiety provide meaningful neuroprotection in humans?
- What is the significance of the dose-response discrepancy in ADAGIO (1mg vs 2mg)?
- Can rasagiline combination with emerging therapies (LRRK2 inhibitors) enhance disease modification?